Related references
Note: Only part of the references are listed.Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial
Alison C. Tree et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer
Edina C. Wang et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2023)
Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy
Takanobu Utsumi et al.
CURRENT ONCOLOGY (2023)
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard et al.
LANCET (2022)
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
Nicholas D. James et al.
JNCI CANCER SPECTRUM (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial
Linda G. W. Kerkmeijer et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer
Scott C. Morgan et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2021)
Multi-institutional retrospective analysis of ultrahypofractionated radiotherapy for Japanese prostate cancer patients
Hiromichi Ishiyama et al.
SCIENTIFIC REPORTS (2021)
Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial
Julia R. Murray et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S. Hofman et al.
LANCET (2020)
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
Sarah Burdett et al.
EUROPEAN UROLOGY (2019)
Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
Akram Saad et al.
RADIATION ONCOLOGY (2017)
Do Prostate Cancer Patients With Markedly Elevated PSA Benefit From Radiation Therapy? A Population-based Study
Yaacov R. Lawrence et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
Nationwide multi-institutional retrospective analysis of high-dose-rate brachytherapy combined with external beam radiotherapy for localized prostate cancer: An Asian Prostate HDR-BT Consortium
Hiromichi Ishiyama et al.
BRACHYTHERAPY (2017)
Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation
Amol K. Narang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: Outcome and toxicity
Yasuhiro Yamada et al.
BRACHYTHERAPY (2015)
The Natural History and Predictors of Outcome Following Biochemical Relapse in the Dose Escalation Era for Prostate Cancer Patients Undergoing Definitive External Beam Radiotherapy
Zachary S. Zumsteg et al.
EUROPEAN UROLOGY (2015)
Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature
Jurgen J. Futterer et al.
EUROPEAN UROLOGY (2015)
Very-high-risk localized prostate cancer: definition and outcomes
D. Sundi et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2014)
The utility of prostate-specific antigen in the management of advanced prostate cancer
E. David Crawford et al.
BJU INTERNATIONAL (2013)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis
Alessia Guarneri et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Treatment Outcomes in Non-Metastatic Prostate Cancer Patients With Ultra-High Prostate-Specific Antigen
Patricia Tai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS
George Rodrigues et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
EXTREME-RISK PROSTATE ADENOCARCINOMA PRESENTING WITH PROSTATE-SPECIFIC ANTIGEN (PSA) >40 NG/ML: PROGNOSTIC SIGNIFICANCE OF THE PRERADIATION PSA NADIR
Abraham S. Alexander et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men
T Fukagai et al.
BJU INTERNATIONAL (2006)